Table 1 Summary of acetylation defects observed in various cancers

From: Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor

Leukemia

HAT fusions

HDAC mediated

 

MOZ/CBP

PML/RARalpha

 

MOZ/p300

PLZF/RARalpha

 

MOZ/TIF-2

AML1 fusion

 

MLL/CBP

 
 

MLL/p300

 

Lymphoma

 

BCL6

  

STAT5

Epithelial cancers

p300 mutations in colorectal, gastric, breast, pancreatic carcinomas/cancer cell lines

Gastric cancer

Elevated expression of HDAC1

Prostate cancer

Elevated expression of HDAC1

Colon cancer

Elevated expression of HDAC1 and HDAC2

Back to article page